Asthma Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Asthma Epidemiology Forecast Report Coverage

Expert Market Research's “Asthma Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of asthma. It projects the future incidence and prevalence rates of asthma cases across various populations. The study covers age, gender, and type as major determinants of the asthma population. The report highlights patterns in the prevalence of asthma over time and projects future trends based on multiple variables.

Asthma Understanding: Disease Overview

Asthma is a chronic inflammatory airway disorder characterized by reversible airflow obstruction, bronchial hyperresponsiveness, and recurring respiratory symptoms including wheezing, shortness of breath, chest tightness, and cough. The disease results from airway inflammation, mucus overproduction, and smooth muscle constriction, leading to episodic exacerbations. Asthma can affect individuals of all ages and presents with varying severity, ranging from intermittent mild symptoms to persistent severe disease. Genetic predisposition and environmental triggers such as allergens, respiratory infections, and pollutants contribute significantly to disease onset and progression across diverse populations worldwide.

Asthma Epidemiology Perspective

The asthma epidemiology division offers information on the patient pool from history to the present, as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the asthma epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for asthma and their trends. The asthma detailed epidemiology segmentation is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• Asthma affects over 260.5 million people worldwide, making it one of the most common chronic respiratory diseases globally and a major contributor to long-term morbidity, healthcare utilization, and preventable mortality.
• Asthma prevalence demonstrates a clear sex-based pattern in younger populations, with higher prevalent cases observed in males compared with females among individuals aged <20 years globally.
• In contrast, epidemiological data indicate a shift in sex distribution after age 20, where females exhibit higher overall asthma prevalence and disease burden compared with males worldwide. For instance, in the year 2021, 135.6 million cases were females and 124.9 million cases were males.
• Regional disparities highlight that the highest asthma prevalence is observed in South Asia, East Asia, and high-income North America, whereas low-SDI regions experience disproportionately higher mortality and disability-adjusted life years (DALYs), reflecting gaps in diagnosis, treatment access, and disease management.
• Asthma-related mortality and disability-adjusted life years (DALYs) show increased burden in older adult populations, particularly among females in advanced age groups.

Read more about this report - Request a Free Sample

Country-wise Asthma Epidemiology Segment

The asthma epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Asthma continues to represent a substantial public health burden in the United States. In 2022, approximately 8.2% of the total United States population, equivalent to nearly 26.8 million individuals, were reported to have current asthma. The condition affects both pediatric and adult populations and demonstrates measurable differences across demographic groups. These figures underscore the ongoing clinical and economic impact of asthma nationwide. Sustained public health surveillance and evidence-based management strategies remain critical to reducing disease burden and improving long-term respiratory outcomes.

Asthma: Treatment Overview

Asthma management focuses on long-term inflammation control and rapid symptom relief. First-line therapy includes inhaled corticosteroids to reduce airway inflammation, often combined with long-acting beta-agonists for maintenance treatment. Short-acting bronchodilators provide quick relief during acute symptoms. For moderate-to-severe disease, additional options include leukotriene modifiers, long-acting muscarinic antagonists, and targeted biologic therapies directed at IgE or eosinophilic pathways. Treatment plans are individualized based on severity and control level, with regular monitoring to prevent exacerbations, improve lung function, and enhance overall quality of life.

Key Questions Answered

• What are the key findings of asthma epidemiology in the 8 major markets?
• What will be the total number of patients with asthma across the 8 major markets during the forecast period?
• What was the country-wise asthma epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of cases of asthma during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of asthma during the forecast period of 2026-2035?
• What are the currently available treatments for asthma?
• What are the disease risks, signs, symptoms, and unmet needs of asthma?

Scope of the Asthma Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of asthma based on several factors.
• Asthma Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The asthma report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Asthma Spacers Market

Asthma Treatment Market